P2B-092

Stanford University (Stanford, CA) › P2B-092

P2B-092

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Phase II
Stanford University (Stanford, CA) · Dr. Nolan
consented 2013-03-21

completed

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 1 stomatitis with onset in cycle 3 (2013-05-14); assessed as related to study drug (probable); resolved 2013-05-24.

mild assessed

Grade 2 decreased appetite with onset in cycle 3 (2013-05-13); assessed as not related to study drug (unlikely); resolved 2013-06-03.

moderate assessed

Grade 2 alopecia with onset in cycle 2 (2013-05-07); assessed as related to study drug (probable); not resolved at last follow-up.

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.